scholarly journals FRI0180 Multiple sclerosis risk-alleles study in patients with demyelinating side effects on anti tnf alpha therapy

2017 ◽  
Author(s):  
S Bitoun ◽  
C Verstuyft ◽  
C Miceli-Richard ◽  
J-M Berthelot ◽  
C Richez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Tnf Alpha ◽  
Risk Alleles ◽  
Multiple Sclerosis Risk ◽  
Alpha Therapy

scholarly journals Neurological Complications of Biological Treatment of Psoriasis

Life ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 118
Author(s):  
Mateusz Kamil Ożóg ◽  
Beniamin Oskar Grabarek ◽  
Magdalena Wierzbik-Strońska ◽  
Magdalena Świder
Keyword(s):  
Nervous System ◽  
Side Effects ◽  
Biological Treatment ◽  
Biological Therapy ◽  
Neurological Complications ◽  
Tnf Alpha ◽  
Biological Drugs ◽  
Discontinuation Of Treatment ◽  
The Relationship ◽  
Alpha Therapy

In the available literature, little attention has been paid to the assessment of psoriasis and the biological therapy used for it and the nervous system. The purpose of this article is to discuss the relationship between psoriasis and the nervous system as well as to analyze the mechanisms that lead to neurological complications during anticytokine therapies in psoriasis. However, this connection requires further analysis. The use of biological drugs in psoriasis, although it yields positive therapeutic results, is not without numerous side effects. Serious neurological side effects of the therapy are most often visible with the use of anti-TNF-alpha, which is why patients should be monitored for their potential occurrence. Early detection of complications and rapid discontinuation of treatment with the drug may potentially increase the patient’s chances of a full recovery or improvement of his/her neurological condition. It also seems reasonable that, in the case of complications occurring during anti-TNF-alpha therapy, some of the drugs from other groups should be included in the therapy.

Enrichment for Northern European-derived multiple sclerosis risk alleles in Sardinia

2015 ◽  
Vol 21 (11) ◽  
pp. 1396-1403 ◽  
Author(s):  
A Hadjixenofontos ◽  
PA Gourraud ◽  
V Bakthavachalam ◽  
L Foco ◽  
A Ticca ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Genetic Risk ◽  
Disease Status ◽  
The United States ◽  
Risk Alleles ◽  
Northern European ◽  
Histocompatibility Complex ◽  
Multiple Sclerosis Risk ◽  
Sardinian Population ◽  
Genetic Burden

Background: The list of genomic loci associated with multiple sclerosis (MS) susceptibility outside the major histocompatibility complex (MHC) in patients of Northern European (NE) ancestry has increased to 103. Despite the extraordinarily high MS prevalence in the isolated Sardinian population, the contribution of genetic risk factors to MS in Sardinia is largely not understood. Objective: The objective of this paper is to examine the relevance of non-MHC MS susceptibility variants in Sardinia. Methods: We examined a log-additive MS-specific genetic burden score (MSGB) using 110 NE-derived risk alleles in a dataset of 75 Sardinian cases, 346 Sardinian controls and 177 cases and 1967 controls from the United States (US). Results: Sardinian cases demonstrate a heavier non-MHC MSGB load than Sardinian controls and US cases ( p = 2E-06, p = 1E-06, respectively). Furthermore, Sardinian controls carry a heavier burden than US controls ( p = 2E-14). Our results confirm the limited ability of the 110-SNP MSGB to predict disease status in Sardinia (AUROC = 0.629). Conclusions: Risk alleles discovered in samples of NE ancestry are relevant to MS in Sardinia. Our results suggest a general enrichment of MS susceptibility alleles in Sardinians, encouraging the pursuit of further studies of MS in this population.

scholarly journals TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Freja Lærke Sand ◽  
Simon Francis Thomsen
Keyword(s):  
Side Effects ◽  
Chronic Urticaria ◽  
Treatment Options ◽  
Significant Proportion ◽  
Response Duration ◽  
Immunosuppressive Drugs ◽  
Tnf Alpha ◽  
High Dose ◽  
Duration Of Treatment ◽  
Durable Response

Patients with severe chronic urticaria may not respond to antihistamines, and other systemic treatment options may either be ineffective or associated with unacceptable side effects. We present data on efficacy and safety of adalimumab and etanercept in 20 adult patients with chronic urticaria. Twelve (60%) patients obtained complete or almost complete resolution of urticaria after onset of therapy with either adalimumab or etanercept. Further three patients (15%) experienced partial response. Duration of treatment ranged between 2 and 39 months. Those responding completely or almost completely had a durable response with a mean of 11 months. Six patients (30%) experienced side effects and five patients had mild recurrent upper respiratory infections, whereas one patient experienced severe CNS toxicity that could be related to treatment with TNF-alpha inhibitor. Adalimumab and etanercept may be effective and relatively safe treatment options in a significant proportion of patients with chronic urticaria who do not respond sufficiently to high-dose antihistamines or in whom standard immunosuppressive drugs are ineffective or associated with unacceptable side effects.

scholarly journals Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination

Cell Reports ◽  
2021 ◽  
Vol 34 (10) ◽  
pp. 108835
Author(s):  
Kimberle Shen ◽  
Mike Reichelt ◽  
Roxanne V. Kyauk ◽  
Hai Ngu ◽  
Yun-An A. Shen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Microglial Activation ◽  
Risk Gene ◽  
Multiple Sclerosis Risk
Sign in / Sign up

Export Citation Format

Share Document